Myelodysplastic Syndrome Global Market Report 2024

Description

“Myelodysplastic Syndrome Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on myelodysplastic syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for myelodysplastic syndrome? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The myelodysplastic syndrome market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Type: Myelodysplastic Syndrome With Unilineage Dysplasia; Myelodysplastic Syndrome With Multilineage Dysplasia; Myelodysplastic Syndrome With Ring Sideroblasts; Other Types
2) By Drug: Azacitidine; Lenalidomide; Decitabine; Deferasirox
3) By Treatment: Supportive Therapy; Growth Factors; Chemotherapy; Stem Cell Transplant; Other Treatments
4) By Route Of Administration: Oral; Injectable; Other Routes Of Administrations
5) By End-Users: Hospitals; Homecare; Specialty Centers; Other End-Users
Companies Mentioned: Pfizer Inc.; Johnson and Johnson Limited; AbbVie Inc.; Bayer AG; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Myelodysplastic syndrome (MDS) encompasses a group of conditions characterized by the aberrant development and functioning of bone marrow cells, leading to inefficient production of blood cells. Treatment for myelodysplastic syndrome is aimed at enhancing blood cell counts, alleviating associated symptoms, and retarding the progression of the disease. It's noteworthy that myelodysplastic syndrome (MDS) can evolve into acute myeloid leukemia (AML), a more aggressive form of blood cancer.

Within the spectrum of myelodysplastic syndrome, various subtypes exist, including myelodysplastic syndrome with unilineage dysplasia, myelodysplastic syndrome with multilineage dysplasia, and myelodysplastic syndrome with ring sideroblasts. Myelodysplastic syndrome (MDS) with unilineage dysplasia is a specific classification within the range of MDS conditions. Treatment options for myelodysplastic syndrome encompass a range of drugs such as azacitidine, lenalidomide, decitabine, and deferasirox. Various treatment modalities are employed, including supportive therapy, growth factors, chemotherapy, and stem cell transplantation. These treatments can be administered through multiple routes, including oral, injectable, and others, and are delivered in diverse healthcare settings, such as hospitals, homecare, specialty centers, and more.

The myelodysplastic syndrome market research report is one of a series of new reports from The Business Research Company that provides myelodysplastic syndrome market statistics, including myelodysplastic syndrome industry global market size, regional shares, competitors with a myelodysplastic syndrome market share, detailed myelodysplastic syndrome market segments, market trends and opportunities and any further data you may need to thrive in the myelodysplastic syndrome industry. This myelodysplastic syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The myelodysplastic syndrome market size has grown rapidly in recent years. It will grow from $2.3 billion in 2023 to $2.56 billion in 2024 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to increasing prevalence of myelodysplastic syndrome, growing awareness about myelodysplastic syndrome treatment, rising healthcare spending, government initiatives.

The myelodysplastic syndrome market size is expected to see rapid growth in the next few years. It will grow to $3.78 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to aging population, adoption of combination therapies, investment in hematologic research, personalized medicine. Major trends in the forecast period include innovative treatments for myelodysplastic syndrome, advancements in diagnostic tools and techniques, clinical trials, collaborative research.

The myelodysplastic syndrome (MDS) market is poised for growth, driven by the rising incidence of rare blood cancers. These uncommon blood cancers, categorized as hematologic malignancies, have a low occurrence rate within the population and originate in the cells of the bone marrow, lymph nodes, and other elements of the blood and immune system. MDS treatment is centered on managing the condition, improving blood cell production, and addressing related symptoms to prevent the progression of blood cancer in the bone marrow. For example, the Leukemia Foundation, a charitable organization in Australia, reported that more than 110,000 individuals are currently grappling with blood disorders as of June 2021. Moreover, it is anticipated that by 2035, the number of Australians affected by blood disorders will surpass 275,000. Hence, the increasing prevalence of blood cancers is a driving force behind the growth of the myelodysplastic syndrome (MDS) market.

The myelodysplastic syndrome (MDS) market is poised for expansion, driven by the expected surge in the number of bone marrow transplants. Bone marrow transplants are medical procedures in which damaged or diseased bone marrow is replaced with healthy stem cells to treat various conditions. MDS is characterized by bone marrow failure, which occurs due to the clonal expansion of somatically mutated hematopoietic stem cells. Bone marrow transplantation can effectively address MDS by replacing aberrant stem cells with healthy ones. For example, in 2021, a total of 5,073 unrelated and 4,276 related bone marrow and cord blood transplants were conducted in the United States and reported to the Center for International Blood and Marrow Transplant Research (CIBMTR), as per data from the Health Resources and Services Administration, a US-based government agency. Consequently, the growth of the myelodysplastic syndrome market is being primarily fueled by the increasing number of bone marrow transplants.

The elevated expenses linked to myelodysplastic syndrome treatment can have a profound effect on the growth of the myelodysplastic syndrome (MDS) market, potentially limiting patient access and impeding overall market expansion. For instance, a report published by Springer Nature Group in November 2022 revealed that treatment costs have been notably high, particularly with regards to transfusions. In fact, these transfusions accounted for 81.3% of supportive care costs for patients transitioning to acute myeloid leukemia (AML) and 65.7% of supportive care costs. Consequently, the high cost of myelodysplastic syndrome treatment is posing a challenge to the market's growth.

Prominent companies within the myelodysplastic syndrome (MDS) market are dedicated to pioneering novel treatments to fortify their market presence. For instance, in July 2021, Genentech Inc., a US-based biotechnology firm, introduced Venclexta (venetoclax) in conjunction with azacitidine for the treatment of myelodysplastic syndrome (MDS) following approval from the US Food and Drug Administration (FDA). This approval encompasses the treatment of adult patients diagnosed with intermediate, high-risk, and very high-risk myelodysplastic syndromes (MDS). This groundbreaking therapy aims to expedite the development of medications intended to address severe or life-threatening conditions, with preliminary data suggesting substantial enhancements compared to existing treatments.

In November 2021, Merck & Co. Inc., a US-based pharmaceutical company, acquired Acceleron Pharma Inc. for an undisclosed amount. With this acquisition, Merck & Co. Inc. aims to expand its cardiovascular portfolio and further strengthen its commercial development strategy, addressing the urgent medical need to reach even more patients. Acceleron Pharma Inc. is a US-based clinical-stage biopharmaceutical company that develops medicines for myelodysplastic syndrome (MDS).

Major players in the myelodysplastic syndrome market are Pfizer Inc., Johnson and Johnson Limited, AbbVie Inc., Bayer AG, Novartis AG, Merck & Co., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., Takeda Pharmaceutical Company Limited, Medtronic PLC, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Ltd., Jazz Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Lupin Limited, BeiGene, Janssen Biotech, Accord Healthcare, Acceleron Pharma Inc.

North America was the largest region in the myelodysplastic syndrome market in 2023. The regions covered in myelodysplastic syndrome (MDS) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the myelodysplastic syndrome (MDS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The myelodysplastic syndrome (MDS) market consists of revenues earned by entities by providing experimental therapies, targeted therapies and blood transfusion. The market value includes the value of related goods sold by the service provider or included within the service offering. The myelodysplastic syndrome (MDS) market also consists of sales of erythropoiesis-stimulating agents (ESAs) and immunomodulatory drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r12266

1. Executive Summary

2. Myelodysplastic Syndrome Market Characteristics

3. Myelodysplastic Syndrome Market Trends And Strategies

4. Myelodysplastic Syndrome Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Myelodysplastic Syndrome Market Size and Growth

5.1. Global Myelodysplastic Syndrome Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Myelodysplastic Syndrome Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Myelodysplastic Syndrome Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Myelodysplastic Syndrome Market Segmentation

6.1. Global Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Myelodysplastic Syndrome With Unilineage Dysplasia
Myelodysplastic Syndrome With Multilineage Dysplasia
Myelodysplastic Syndrome With Ring Sideroblasts
Other Types
6.2. Global Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Azacitidine
Lenalidomide
Decitabine
Deferasirox
6.3. Global Myelodysplastic Syndrome Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Supportive Therapy
Growth Factors
Chemotherapy
Stem Cell Transplant
Other Treatments
6.4. Global Myelodysplastic Syndrome Market, Segmentation By Route Of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oral
Injectable
Other Routes Of Administrations
6.5. Global Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Homecare
Speciality Centres
Other End-Users

7. Myelodysplastic Syndrome Market Regional And Country Analysis

7.1. Global Myelodysplastic Syndrome Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Myelodysplastic Syndrome Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Myelodysplastic Syndrome Market

8.1. Asia-Pacific Myelodysplastic Syndrome Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Myelodysplastic Syndrome Market

9.1. China Myelodysplastic Syndrome Market Overview
9.2. China Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Myelodysplastic Syndrome Market

10.1. India Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Myelodysplastic Syndrome Market

11.1. Japan Myelodysplastic Syndrome Market Overview
11.2. Japan Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Myelodysplastic Syndrome Market

12.1. Australia Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Myelodysplastic Syndrome Market

13.1. Indonesia Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Myelodysplastic Syndrome Market

14.1. South Korea Myelodysplastic Syndrome Market Overview
14.2. South Korea Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Myelodysplastic Syndrome Market

15.1. Western Europe Myelodysplastic Syndrome Market Overview
15.2. Western Europe Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Myelodysplastic Syndrome Market

16.1. UK Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Myelodysplastic Syndrome Market

17.1. Germany Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Myelodysplastic Syndrome Market

18.1. France Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Myelodysplastic Syndrome Market

19.1. Italy Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Myelodysplastic Syndrome Market

20.1. Spain Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Myelodysplastic Syndrome Market

21.1. Eastern Europe Myelodysplastic Syndrome Market Overview
21.2. Eastern Europe Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Myelodysplastic Syndrome Market

22.1. Russia Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Myelodysplastic Syndrome Market

23.1. North America Myelodysplastic Syndrome Market Overview
23.2. North America Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Myelodysplastic Syndrome Market

24.1. USA Myelodysplastic Syndrome Market Overview
24.2. USA Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Myelodysplastic Syndrome Market

25.1. Canada Myelodysplastic Syndrome Market Overview
25.2. Canada Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Myelodysplastic Syndrome Market

26.1. South America Myelodysplastic Syndrome Market Overview
26.2. South America Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Myelodysplastic Syndrome Market

27.1. Brazil Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Myelodysplastic Syndrome Market

28.1. Middle East Myelodysplastic Syndrome Market Overview
28.2. Middle East Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Myelodysplastic Syndrome Market

29.1. Africa Myelodysplastic Syndrome Market Overview
29.2. Africa Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Myelodysplastic Syndrome Market Competitive Landscape And Company Profiles

30.1. Myelodysplastic Syndrome Market Competitive Landscape
30.2. Myelodysplastic Syndrome Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Johnson and Johnson Limited
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. AbbVie Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Bayer AG
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Novartis AG
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Myelodysplastic Syndrome Market Other Major And Innovative Companies

31.1. Merck & Co.
31.2. Sanofi S.A.
31.3. Bristol-Myers Squibb Company
31.4. AstraZeneca Plc.
31.5. Takeda Pharmaceutical Company Limited
31.6. Medtronic Plc
31.7. Eli Lilly and Company
31.8. Amgen Inc.
31.9. Boehringer Ingelheim International GmbH
31.10. Otsuka Pharmaceutical Co. Ltd.
31.11. Teva Pharmaceutical Industries Ltd.
31.12. Astellas Pharma Inc.
31.13. Daiichi Sankyo Company Ltd.
31.14. Jazz Pharmaceuticals
31.15. Dr. Reddy's Laboratories Ltd.

32. Global Myelodysplastic Syndrome Market Competitive Benchmarking

33. Global Myelodysplastic Syndrome Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Myelodysplastic Syndrome Market

35. Myelodysplastic Syndrome Market Future Outlook and Potential Analysis

35.1 Myelodysplastic Syndrome Market In 2028 - Countries Offering Most New Opportunities
35.2 Myelodysplastic Syndrome Market In 2028 - Segments Offering Most New Opportunities
35.3 Myelodysplastic Syndrome Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer